{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T21:07:32Z","timestamp":1778965652319,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.eimce.2021.05.011","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T03:51:24Z","timestamp":1626925884000},"page":"550-556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention?"],"prefix":"10.1016","volume":"40","author":[{"given":"Maria Jes\u00fas","family":"P\u00e9rez-El\u00edas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Podzamczer Palter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Ventayol Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Jarr\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dar\u00edo","family":"Rubio-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Rubio-Terr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimce.2021.05.011_bib0005","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1001\/jama.1987.03400110099035","article-title":"Approval of zidovudine (AZT) for acquired immunodeficiency syndrome. A challenge to the medical and pharmaceutical communities","volume":"258","author":"Brook","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.eimce.2021.05.011_bib0010","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1016\/0002-9343(90)90414-9","article-title":"Susceptibility to nucleoside analogues of zidovudine resistant isolates of human immunodeficiency virus","volume":"88","author":"Richman","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.eimce.2021.05.011_bib0015","unstructured":"Unidad de vigilancia de VIH y conductas de riesgo. Mortalidad por VIH y sida en Espa\u00f1a, a\u00f1o 2017. Evoluci\u00f3n 1981-2017. Centro Nacional de Epidemiolog\u00eda, Instituto de Salud Carlos III\/Plan Nacional sobre el Sida, Direcci\u00f3n General de Salud P\u00fablica, Calidad e Innovaci\u00f3n. Madrid; 2019. [Accessed 29 May 2020]. Available from: https:\/\/www.mscbs.gob.es\/ca\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/vigilancia\/doc\/MortalidadXVIH2017.pdf."},{"key":"10.1016\/j.eimce.2021.05.011_bib0020","unstructured":"Direcci\u00f3n General de Salud P\u00fablica, Calidad e Innovaci\u00f3n. Informe de evaluaci\u00f3n Plan estrat\u00e9gico de prevenci\u00f3n y control del VIH e ITS de 2013-2016. Plan Nacional del SIDA. 2018. [Accessed 20 June 2019]. Available from: https:\/\/www.mscbs.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/planesEstrat\/informeEvaluacion_VDweb_12Dicbre18.pdf."},{"key":"10.1016\/j.eimce.2021.05.011_bib0025","unstructured":"Unidad de vigilancia del VIH y conductas de riesgo. Estimaci\u00f3n del Continuo de Atenci\u00f3n del VIH en Espa\u00f1a 2016. Madrid: Centro Nacional de Epidemiolog\u00eda \u2013 Instituto de Salud Carlos III \/Plan Nacional sobre el Sida \u2013 Direcci\u00f3n General de Salud P\u00fablica, Calidad e Innovaci\u00f3n; 2019. [Accessed 10 March 2020]. Available from: https:\/\/www.mscbs.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/docs\/ESTIMACION_DEL_CONTINUO_DE_ATENCION_DEL_VIH_EN_ESPANA.pdf."},{"key":"10.1016\/j.eimce.2021.05.011_bib0030","first-page":"11","article-title":"Actualizaci\u00f3n epidemiol\u00f3gica espa\u00f1ola de los objetivos 2020","volume":"8","author":"D\u00edaz","year":"2020","journal-title":"Rev Multidisciplinar del Sida"},{"key":"10.1016\/j.eimce.2021.05.011_bib0035","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1377\/hlthaff.2018.05391","article-title":"Twenty years of antiretroviral therapy for people living with HIV: global costs, health achievements, economic benefits","volume":"38","author":"Forsythe","year":"2019","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.eimce.2021.05.011_bib0040","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimce.2021.05.011_bib0045","author":"UNAIDS"},{"key":"10.1016\/j.eimce.2021.05.011_bib0050","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.jfda.2013.09.043","article-title":"HIV treatment as prevention: the key to an AIDS-free generation","volume":"21","author":"Hull","year":"2013","journal-title":"J Food Drug Anal"},{"key":"10.1016\/j.eimce.2021.05.011_bib0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.12708","article-title":"Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps","volume":"20 Suppl 1","author":"Boyd","year":"2019","journal-title":"HIV Med"},{"key":"10.1016\/j.eimce.2021.05.011_bib0060","series-title":"Decision modelling for health economic evaluation","author":"Briggs","year":"2007"},{"key":"10.1016\/j.eimce.2021.05.011_bib0065","series-title":"Applied methods of cost-effectiveness analysis in health care","author":"Gray","year":"2012"},{"key":"10.1016\/j.eimce.2021.05.011_bib0070","first-page":"2","article-title":"Probabilistic analysis: sensitivity analysis or main result?","volume":"1","author":"Rubio-Terr\u00e9s","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.eimce.2021.05.011_bib0075","series-title":"El valor monetario de una vida estad\u00edstica en Espa\u00f1a. Estimaci\u00f3n en el contexto de los accidentes de tr\u00e1fico","author":"Abell\u00e1n","year":"2011"},{"key":"10.1016\/j.eimce.2021.05.011_bib0080","unstructured":"Instituto Nacional de Estad\u00edstica. Contabilidad Regional de Espa\u00f1a. Serie 2000\u20132018. [Accessed 19 March 2020]. Available from: https:\/\/www.ine.es\/daco\/daco42\/cre00\/b2010\/pr_cre.xlsx."},{"key":"10.1016\/j.eimce.2021.05.011_bib0085","unstructured":"PIB de Espa\u00f1a. Producto interior bruto. 1981\u20131999. [Accessed 19 March 2020]. Available from: https:\/\/datosmacro.expansion.com\/pib\/espana."},{"key":"10.1016\/j.eimce.2021.05.011_bib0090","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/QAD.0000000000001335","article-title":"Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population","volume":"31","author":"Gueler","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.eimce.2021.05.011_bib0095","first-page":"125","article-title":"El valor monetario de la vida estad\u00edstica en Espa\u00f1a a trav\u00e9s de las preferencias declaradas","volume":"183","author":"Mart\u00ednez","year":"2007","journal-title":"Hacienda P\u00fablica Espa\u00f1ola\/Revista de Econom\u00eda P\u00fablica"},{"key":"10.1016\/j.eimce.2021.05.011_bib0100","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40273-018-0672-z","article-title":"Discounting in economic evaluations","volume":"36","author":"Attema","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.eimce.2021.05.011_bib0105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.eimce.2021.05.011_bib0110","doi-asserted-by":"crossref","first-page":"i7","DOI":"10.1093\/ije\/dyq016","article-title":"Spectrum: a model platform for linking maternal and child survival interventions with AIDS, family planning, and demographic projections","volume":"39 Suppl 1","author":"Stover","year":"2010","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.eimce.2021.05.011_bib0115","unstructured":"Spectrum A policy development and planning tool for improved health. Version 5.86. Avenir Health. [Accessed: 19 March 2020]. Available from URL: https:\/\/www.avenirhealth.org\/software-spectrum.php."},{"key":"10.1016\/j.eimce.2021.05.011_bib0120","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2307\/2347162","article-title":"The Holt-Winters forecasting procedure","volume":"27","author":"Chatfield","year":"1978","journal-title":"Appl Statist"},{"key":"10.1016\/j.eimce.2021.05.011_bib0125","author":"SINIVIH. Sistema de informaci\u00f3n sobre nuevos diagn\u00f3sticos de VIH"},{"key":"10.1016\/j.eimce.2021.05.011_bib0130","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/QAD.0000000000000298","article-title":"Estimating per-act HIV transmission risk: a systematic review","volume":"28","author":"Patel","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.eimce.2021.05.011_bib0135","series-title":"ART sales in Spain, 1987\u20131996","author":"IQVIA","year":"2020"},{"key":"10.1016\/j.eimce.2021.05.011_bib0140","author":"Direcci\u00f3n General de Salud P\u00fablica, Calidad e Innovaci\u00f3n"},{"key":"10.1016\/j.eimce.2021.05.011_bib0145","series-title":"ART sales in Spain, 2017-2018","author":"IQVIA","year":"2020"},{"key":"10.1016\/j.eimce.2021.05.011_bib0150","first-page":"568","article-title":"C\u00e1lculo de los costes del sida en Espa\u00f1a mediante t\u00e9cnicas de simulaci\u00f3n","volume":"104","author":"Anto\u00f1anzas","year":"1995","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.eimce.2021.05.011_bib0155","unstructured":"Proyecto SROI-EM. Impacto cl\u00ednico, asistencial, econ\u00f3mico y social del abordaje ideal de la esclerosis m\u00faltiple en comparaci\u00f3n con el abordaje actual. Informe final (4 de junio de 2018). [Accessed 4 February 2021]. Available from: https:\/\/www.roche.es\/content\/dam\/rochexx\/roche-es\/roche-farma\/neurociencias\/Informe-SROIEM.pdf."},{"key":"10.1016\/j.eimce.2021.05.011_bib0160","series-title":"Valor social de un abordaje ideal en insuficiencia cardiaca. An\u00e1lisis econ\u00f3mico utilizando la metodolog\u00eda SROI","author":"Merino","year":"2017"},{"key":"10.1016\/j.eimce.2021.05.011_bib0165","unstructured":"Retorno Social de la Inversi\u00f3n de un abordaje ideal de la psoriasis. Informe de resultados 2016. Available from URL: http:\/\/weber.org.es\/wp-content\/uploads\/2017\/10\/Informe-proyecto-SROI-Psoriasis.pdf. [Accessed: 4 February 2021]."},{"key":"10.1016\/j.eimce.2021.05.011_bib0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/CEOR.S121093","article-title":"Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer","volume":"9","author":"Isla","year":"2016","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.eimce.2021.05.011_bib0175","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","article-title":"Propuesta de gu\u00eda para la evaluaci\u00f3n econ\u00f3mica aplicada a las tecnolog\u00edas sanitarias","volume":"24","author":"L\u00f3pez Bastida","year":"2010","journal-title":"Gac Sanit"},{"key":"10.1016\/j.eimce.2021.05.011_bib0180","series-title":"Gu\u00eda y recomendaciones para la realizaci\u00f3n y presentaci\u00f3n de evaluaciones econ\u00f3micas y an\u00e1lisis de impacto presupuestario de medicamentos en el \u00e1mbito del Catsalut","year":"2014"},{"key":"10.1016\/j.eimce.2021.05.011_bib0185","unstructured":"Indicadores sobre gasto farmac\u00e9utico y sanitario. Serie Gasto farmac\u00e9utico y sanitario: periodo junio 2014 a marzo 2020. Ministerio de Hacienda. [Accessed 4 June 2020]. Available from: https:\/\/www.hacienda.gob.es\/CDI\/Gasto%20Sanitario\/SERIE%20Gasto%20Farmac%C3%A9utico%20y%20Sanitario.xlsx."},{"key":"10.1016\/j.eimce.2021.05.011_bib0190","doi-asserted-by":"crossref","DOI":"10.1177\/2325958218821962","article-title":"Why maximizing quality-adjusted life years, rather than reducing HIV incidence, must remain our objective in addressing the HIV\/AIDS epidemic","volume":"18","author":"Nosyk","year":"2019","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"10.1016\/j.eimce.2021.05.011_bib0195","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1287\/mnsc.6.3.324","article-title":"Forecasting sales by exponentially weighted moving averages","volume":"6","author":"Winters","year":"1960","journal-title":"Management Sci"},{"key":"10.1016\/j.eimce.2021.05.011_bib0200","unstructured":"Global investment in HIV cure research and development in 2018. AVAC. Global Advocacy for HIV Prevention. 2019. [Accessed 4 June 2020]. Available from URL: https:\/\/www.avac.org\/sites\/default\/files\/resource-files\/cureRT_july2019.pdf."},{"key":"10.1016\/j.eimce.2021.05.011_bib0205","unstructured":"ONUSIDA. 90-90-90: Un ambicioso objetivo de tratamiento para contribuir al fin de la epidemia de sida. [Accessed 4 June 2020]. Available from: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/90_90_90_es.pdf."}],"container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X21001313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X21001313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:21:15Z","timestamp":1778962875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2529993X21001313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2529993X21001313"],"URL":"https:\/\/doi.org\/10.1016\/j.eimce.2021.05.011","relation":{},"ISSN":["2529-993X"],"issn-type":[{"value":"2529-993X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention?","name":"articletitle","label":"Article Title"},{"value":"Enfermedades infecciosas y microbiologia clinica (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimce.2021.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2021.05.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica.","name":"copyright","label":"Copyright"}]}}